Trial reportThe European respiratory journal2021
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.
Trial report in The European respiratory journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 56 citations in OpenAlex.
- Feasibility of Home-Based Spirometry Monitoring as a Decentralized Clinical Trial Component in Patients with Chronic Obstructive Pulmonary Disease and Other Respiratory Diseases.Healthcare (Basel, Switzerland) · 2026Article
- Expanding Remote Patient Monitoring for Pre-Lung Transplant Candidates With Interstitial Lung Disease.Clinical transplantation · 2026Article
- Patient Experiences of Digital Technology Use in Interstitial Lung Disease (PRODIGY-ILD Study): Qualitative Study Using Reflexive Thematic Analysis.JMIR human factors · 2026Observational
- Design of a randomized controlled trial comparing hybrid care with standard care for people with pulmonary fibrosis.Respiratory research · 2026Article
- Clinical Use of Home Spirometry in Children With Cystic Fibrosis.Pediatric pulmonology · 2026Article
- Telemedicine in chronic lung disease management: progress and prospects.The Korean journal of internal medicine · 2026Review
- Healthcare professionals' perspectives on implementation of home monitoring in individuals with pulmonary fibrosis.ERJ open research · 2026Article
- Remote monitoring of spirometry and oximetry in patients with connective tissue disease related interstitial lung disease: a prospective observational cohort study.BMC pulmonary medicine · 2025Observational
- Active Antigen-Specific Adaptive Immune Responses Are Shared among Patients with Progressive Fibrotic Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025Article
- Online home spirometry in national pulmonary fibrosis care: insights from daily practice.ERJ open research · 2025Article
- Home is where spirometry should be: enhancing care for individuals with pulmonary fibrosis.ERJ open research · 2025Article
- Home Monitoring in Interstitial Lung Disease: Protocol for a Real-World Observational Study.JMIR research protocols · 2025Article
- Home Spirometry for Post-COVID Recovery: A Clinical Validation Study of an Ultrasonic Device.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Article
- Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2025Article
- Monitoring respiratory function with telemedicine devices in asthmatic children.Frontiers in medicine · 2025Article
- European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).PloS one · 2025Article
- The role of digital health in respiratory diseases management: a narrative review of recent literature.Frontiers in medicine · 2025Review
- Protocol and research program of the European registry and biobank for interstitial lung diseases (eurILDreg).BMC pulmonary medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 7 countries.
Funding
Abstract
backgroundData from the INMARK trial were used to investigate the feasibility and validity of home spirometry as a measure of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
methodsSubjects with IPF and preserved forced vital capacity (FVC) were randomised to receive nintedanib or placebo for 12 weeks followed by open-label nintedanib for 40 weeks. Clinic spirometry was conducted at baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 52. Subjects were asked to perform home spirometry at least once a week and ideally daily. Correlations between home- and clinic-measured FVC and rates of change in FVC were assessed using Pearson correlation coefficients.
resultsIn total, 346 subjects were treated. Mean adherence to weekly home spirometry decreased over time but remained above 75% in every 4-week period. Over 52 weeks, mean adherence was 86%. Variability in change from baseline in FVC was greater when measured by home rather than clinic spirometry. Strong correlations were observed between home- and clinic-measured FVC at all time-points (r=0.72-0.84), but correlations between home- and clinic-measured rates of change in FVC were weak (r=0.26 for rate of decline in FVC over 52 weeks).
conclusionHome spirometry was a feasible and valid measure of lung function in patients with IPF and preserved FVC, but estimates of the rate of FVC decline obtained using home spirometry were poorly correlated with those based on clinic spirometry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.